Literature DB >> 10216646

Double blind randomized comparative evaluation of nimesulide and paracetamol as antipyretics.

P K Goyal1, J Chandra, G Unnikrishnan, S Kumari, S M Passah.   

Abstract

OBJECTIVE: To compare the efficacy and safety of nimesulide and paracetamol as antipyretic agents.
DESIGN: Double blind, randomized clinical trial.
METHODS: Hospitalized patients having fever due to a variety of infections were given either drug in a randomized manner. (Nimesulide group = 49, Paracetamol group = 50). Serial axillary temperature was recorded after drug administration and side effects monitored.
RESULTS: The mean temperature after one hour of drug administration was significantly lower in nimesulide group (p < 0.05). Significantly fewer doses of nimesulide were required to bring down the temperature on the first day (p < 0.001). The mean maximum temperature recorded on second and third day was significantly lower in the nimesulide group (p < 0.05). Adverse reactions were seen in the form of epigastric pain and vomiting in one patient in Nimesulide group and three in paracetamol group.
CONCLUSION: Nimesulide is more effective than paracetamol as an antipyretic agent and is safe for use in infants and children.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10216646

Source DB:  PubMed          Journal:  Indian Pediatr        ISSN: 0019-6061            Impact factor:   1.411


  4 in total

1.  Antipyretic effects of nimesulide, paracetamol and ibuprofen-paracetamol.

Authors:  A Lal; S Gomber; B Talukdar
Journal:  Indian J Pediatr       Date:  2000-12       Impact factor: 1.967

Review 2.  Paracetamol for treating fever in children.

Authors:  M Meremikwu; A Oyo-Ita
Journal:  Cochrane Database Syst Rev       Date:  2002

3.  Nimesulide controversy in India--time to learn.

Authors:  Arun Biswas; Krishan Singhal
Journal:  Drug Saf       Date:  2003       Impact factor: 5.228

Review 4.  Antipyretics in children.

Authors:  Jagdish Chandra; Shishir Kumar Bhatnagar
Journal:  Indian J Pediatr       Date:  2002-01       Impact factor: 5.319

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.